PPAR Agonists Modulate Immune Response in Sepsis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis and septic shock are inadequate in effectively managing organ dysfunction and mortality, as they primarily focus on infection control and hemodynamic stabilization without addressing the underlying dysregulated immune response and organ failure.
Innovation Solution
The use of PPAR agonists such as lanifibranor, bezafibrate, fenofibrate, pemafibrate, seladelpar, saroglitazar, pioglitazone, rosiglitazone, and specific compounds like Cpd.1, or their pharmaceutically acceptable salts, to treat sepsis and liver failure by reducing TNFα and MCP1 secretion, cytokine production, and improving organ function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments focusing on infection control and hemodynamic stabilization are used, then immediate life-threatening conditions are addressed, but underlying dysregulated immune response and organ dysfunction are not effectively managed
Solution Approach 1:
The patent introduces PPAR agonists as intermediary substances that mediate between the dysregulated immune system and organ dysfunction. These compounds activate PPAR receptors to modulate gene expression, thereby bridging the gap between immune control and organ function protection without requiring complex multi-modal interventions
Solution Approach 2:
The treatment approach changes the biochemical parameter landscape by introducing PPAR agonists that alter gene expression profiles and inflammatory cytokine levels. This shifts the system from a state of dysregulated immune response to a more balanced state, improving organ dysfunction management through molecular parameter modification
2Ease of operation
If PPAR agonists are used to modulate immune response, then inflammatory cytokines are reduced and organ function improves, but the mechanism involves complex gene regulation and cellular pathways
Solution Approach 1:
The patent extracts the core therapeutic action from complex immune dysregulation by identifying and targeting the PPAR receptor pathway. By focusing on this specific molecular target, the treatment simplifies the approach to immune modulation while still achieving broad effects on inflammatory responses and organ protection through a single class of compounds
3Reliability
If rapid control of infection and hemodynamic stabilization are prioritized, then immediate survival is improved, but mortality remains high due to unaddressed immune dysregulation
Solution Approach 1:
The patent applies preliminary action by introducing PPAR agonists early in the sepsis course, before irreversible organ damage occurs. This proactive approach modulates the immune response in advance, preventing the progression to severe organ dysfunction and reducing mortality without delaying critical interventions
Solution Approach 2:
The treatment ensures continuity of useful action by maintaining PPAR activation throughout the critical period of sepsis. This sustained molecular intervention continuously modulates immune responses and protects organ function, bridging the gap between initial stabilization and long-term recovery
Data Source
AI summary
The invention relates to compounds for use in the treatment of sepsis.